🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Amazing discussion. Worth listening to 1) understand mUC in 2025-2026 and 2) learn strategies for how to deliver a compelling discussion. Well done!

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

The fact this was NOT a plenary at ASCO clearly demonstrates pharma’s strong influence over academic oncology in my opinion. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Fantastic discussion of key abstracts at #ASCO25 in the context of our #GU cancer patients w/ Tian Zhang, MD, MHS Petros Grivas Karine Tawagi MD at #OncForum2025 including CREST, SURE02, EV302, NIAGARA, KEYNOTE564, PDIGREE, ARC20, looking forward to AMPLITUDE read out Tuesday!

❓Curious about visa info for hematology oncology fellowship programs? Scan the QR code to explore program details! So honored to share the results at #ASCO25 IMGCoP and great work done by the VAM committee Lei Deng, MD (He/Him) Masood Pasha Syed MBBS MD IMG Oncologists

MultiD mgmt of RCC by Benjamin L Maughan w/ insightful pt perspective 🌀using risk calculators like ASSURE to counsel pts on recurrence & benefit of adj pembro #KN564 🌀selective role of cytoreductive nephrectomy 🌀counseling on irAEs -35% on ipi/nivo get steroids #ASCO25

Come say hello at our #HARMONY TIP 1L mHSPC w/ ADT/#niraparib/#abiraterone open UTSW Simmons Cancer Center poster #319a and #RWE of HRR alteration and PARP use by race/ethnicity poster #276 Tian Zhang, MD, MHS Charles Jiang MD, MPH OncoAlert

Congratulations to the 2025 class of ASCO Leadership Development Program Education Scholars! This year has been an incredible journey of learning & growth. Grateful to have such an inspiring & dedicated group in my life! Karine Tawagi MD Sujith Thejal Srikumar Inas Abuali, MD

Great GU poster session #ASCO25 📍ctDNA in mUC (n=36) on EV: 92% were (+) Kevin Reyes Vadim Koshkin MD 📍real-world EV toxicities & d/c +survival @ronmamanti 📍KIM-1 in mRCC Mark Machaalani Toni Choueiri, MD Wenxin (Vincent) Xu 📍our University of Illinois Cancer Center team on HER3 overexpression in PCa

Proud of my mentor Michael Ong presenting impt international #IRONMAN data: 🚹 mCSPC w/ ADT + ARPI 🌀PSA of >= 0.2 at 6-12mo = worse px (mOS 30mo) ➡️consider #TRIPLESWITCH intensification trial now open 🌀PSA<0.2 at 6-12mo = good px ➡️ consider #DEESCALATE trial #ASCO25

#AMPLITUDE: role of PARPi in mCSPC? ➡️for fellows: PARPi only approved in mCRPC currently 🚹nira + abi in pts w/ HRRm vs abi in mCSPC 🌀met rPFS; but only 36% in control got PARPi at progression❗️ ❓OS immature, sequencing w/ pluvicto/chemo, long-term AEs: MDS/AML #ASCO25

Wonderful to see you as always my dear friend Tian Zhang, MD, MHS congratulations on 2 amazing talks #ASCO25 ASCO Karine Tawagi MD OncoAlert

Recognizing Top Oncologists, Top Women Oncologists, and Rising Stars from ASCO 2025 at Times Square! Dr Amol Akhade | Paolo Tarantino | Aakash Desai, MD, MPH, FASCO | Stephen V Liu, MD | Hidehito HORINOUCHI | Toni Choueiri, MD | Yakup Ergün | Neeraj Agarwal, MD, FASCO | Andrea Necchi | Sharlene Gill, MD, MPH, MBA, FASCO | Aya Mohamed | MSc, MD 🎗 |

A huge congrats to our 2024-2025 heme/onc graduates + their families, it’s been a pleasure to celebrate you all! 🌟 Dr. Lucia Notardonato 🌟 Dr. William Bae 🌟 Dr. Ahmad Nassar 🌟 Dr. Neha Hippalgaonkar 🌟 Dr. Joshua Pothen 🌟 Dr. Elisa Zuccheti

Recognizing the Top Women Oncologists from ASCO 2025 at Times Square. This list is based on the most views on X during #ASCO25. Sharlene Gill, MD, MPH, MBA, FASCO | Aya Mohamed | MSc, MD 🎗 | DrKatyMoore | Stephanie Graff, MD, FACP, FASCO | Dra. María Natalia Gandur Quiroga | Charu Aggarwal, MD, MPH, FASCO | Rebecca Shatsky, MD | Karine Tawagi MD | Tian Zhang, MD, MHS |

Joshua Meeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb